Factors associated with low-level viraemia and virological failure: Results from the Austrian HIV cohort study

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Leierer, Gisela ^a,b   Grabmeier Pfistershammer, Katharina ^c   Steuer, Andrea ^d   Geit, Maria ^e   Sarcletti, Mario ^a   Haas, Bernhard ^f   Kanatschnig, Manfred ^g   Rappold, Michaela ^a,b   Zangerle, Robert ^a   Ledergerber, Bruno ^h   Taylor, Ninon ⁱ  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Austrian HIV Cohort Study   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

^d OTTO WAGNER HOSPITAL   (Austria)

^e KEPLER UNIVERSITY HOSPITAL   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g GENERAL HOSPITAL KLAGENFURT   (Austria)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE; ARTICLE; AUSTRIAN; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CORRELATIONAL STUDY; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION; VIREMIA; VIRUS LOAD; AUSTRIA; BLOOD; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; SUBSTANCE ABUSE; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; AUSTRIA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 84958773264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142923     Document Type: Article

References (25)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. (2008) Lancet 372: 293-299. doi: 10.1016/S0140-6736(08)61113-7 PMID: 18657708
2. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860. PMID: 9516219
3. Panel on Antiretroviral Guidelines for adults and adolescents for the use of ART in HIV-1 infecrted Adults and Adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih. gov/guidelines. Accessed 26th August 2015.
4. European AIDS Clinical Society version 7.1, November 2014. EACS, Brussels, belgium. available at http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 26th August 2015.
5. Vancoillie L, Demecheleer E, Callens S, Vogelaers D, Vandekerckhove L, Mortier V, et al. (2014) Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection. J Antimicrob Chemother 69: 1098-1103. doi: 10.1093/jac/dkt484 PMID: 24335486
6. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3: e46. PMID: 17411338
7. Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, et al. (2005) Residual viraemia in subjects with chronic HIV infection and viral load 50 copies/ml: the impact of highly active antiretroviral therapy. Aids 19: 1843-1847. PMID: 16227792
8. Martin-Blondel G, Saune K, Vu Hai V, Marchou B, Delobel P, Izopet J,et al. (2012) Factors associated with a strictly undetectable viral load in HIV-1-infected patients. HIV Med 13: 568-573. doi: 10.1111/j. 1468-1293.2012.01012.x PMID: 22435457
9. Sire JM, Vray M, Merzouk M, Plantier JC, Pavie J, Maylin S, et al. (2011) Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr 56: 239-243. doi: 10.1097/QAI. 0b013e3182099891 PMID: 21164353
10. Taylor N, Schmid I, Egle A, Greil R, Patsch W, Oberkofler H (2009) Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antivir Ther 14: 1189-1193. doi: 10.3851/IMP1427 PMID: 20032549
11. Amendola A, Marsella P, Bloisi M, Forbici F, Angeletti C, Capobianchi MR (2014) Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays. J Clin Microbiol 52: 2019-2026. doi: 10.1128/JCM.00288-14 PMID: 24671791
12. Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, Berger A (2013) Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia. Med Microbiol Immunol 202: 67-75. doi: 10.1007/s00430-012-0249-y PMID: 22699843
13. Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, et al. (2013) Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level. PLoS One 8: e74024. doi: 10.1371/journal.pone.0074024 PMID: 24023696
14. Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, et al. (2014) Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol 52: 517-523. doi: 10.1128/JCM.02461-13 PMID: 24478482
15. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, et al. (2012) Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54: 724-732. doi: 10.1093/cid/cir936 PMID: 22238167
16. Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, et al. (2013) Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 13: 587-596. doi: 10.1016/S1473-3099(13)70093-8 PMID: 23664333
17. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H (2013) Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 57: 1489-1496. doi: 10.1093/cid/cit529 PMID: 23946221
18. Ribaudo H Lennox J, Currier J (2009) Virological failure endpoint definition in clinical trials: Is using HIV-1RNA threshold 200 copies/mL better than 50 copies/mL? An analysis of the ACTG studies. Paper presented at: Conference on Retroviruses and Opportunistic Infections; Montreal, Canada.
19. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, et al. (2011) Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 204: 515-520. doi: 10.1093/infdis/jir353 PMID: 21791652
20. Djedaini M, Peraldi P, Drici MD, Darini C, Saint-Marc P, Dani C, et al. (2009) Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 386: 96-100. doi: 10.1016/j.bbrc.2009.05.148 PMID: 19501568
21. Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, et al. (2009) Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis 48: 260-262. doi: 10.1086/595707 PMID: 19113986
22. Griffith BP, Mayo DR (2006) Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). J Clin Virol 35: 197-200. PMID: 16253548
23. Lima V, Harrigan R, Montaner JS (2009) Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 51: 3-6. doi: 10.1097/QAI.0b013e31819e721b PMID: 19247185
24. Portman MD, Lacey CJ (2012) Apparent low-level HIV RNA viraemia related to sample processing time. HIV Med 13: 578-579. doi: 10.1111/j.1468-1293.2012.01016.x PMID: 22963641
25. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Piérard D, et al. (2012) HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis 12: 100. PMID: 22530816